IGC Pharma

IGC

Market cap $28.2M

- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the addition of Dominion Medical Associates, Inc., a Richmond, Virginia-based clinical research site within Lightship's site network, to the Company's Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. Dominion Medical Associates will operate under Lightship's expanded access clinical trial model, combining in-clinic assessments with remote and in-home participant activities as part of a flexible hybrid and virtual delivery approach.

POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that its Board of Directors has approved a change in the Company's fiscal year end from March 31 to December 31, effective December 31, 2025. "This is a straightforward but important step in strengthening how we engage with U.S. investors," said Ram Mukunda, CEO of IGC Pharma.

- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that it has entered into a Subscription Agreement (the "2025 SA") with a group of investors for the purchase and sale of an aggregate of 779,997 shares of common stock in a registered direct offering, at a purchase price of $0.30 per share. Gross proceeds from the offering are expected to be approximately $234,000, before deducting estimated offering expenses payable by the Company.

- New Patent Expands IGC Pharma's Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer's Disease - POTOMAC, MD / ACCESS Newswire / December 19, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office (USPTO) has officially issued U.S. Patent No. 12,491,200, covering the Company's novel microdose-based cannabinoid treatment of stuttering (stammering) and Tourette's Syndrome.

POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy momentum surrounding the potential reclassification of cannabis to Schedule III and its implications for the regulated cannabinoid pharmaceutical sector. Recent reports indicating a possible shift in federal scheduling have coincided with renewed market interest across the cannabinoid landscape, reflecting expectations that a clearer federal posture may reduce long-standing friction around research, manufacturing, and financial infrastructure.

POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced it has reached a key enrollment milestone of 65% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. This milestone marks a significant step in advancing IGC-AD1, the Company's proprietary formulation, and demonstrates continued strong momentum toward full enrollment consistent with the goal of completing the trial in early 2026.

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced the publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences," a comprehensive caregiver-focused book sponsored by IGC Pharma and authored by several of the world's leading experts in neuropsychology and dementia care. The book written by renowned clinical neuropsychologists Dr. Juan Carlos Arango-Lasprilla and Dr. Sandra Báez, alongside co-authors Dr. Valeria Villamizar, and Dr. Natalia Valech presents science-based education, practical strategies, and real-life narratives from families impacted by Alzheimer's disease.

POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced advances in MINT-AD, the Multimodal Interpretable Transformer for Alzheimer's. Leveraging data from the Health and Retirement Study (HRS) International Family of Studies, IGC Pharma aims to identify unknown socioeconomic risk factors and their interactions influencing aging and cognitive decline.

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced financial results for the quarter ended September 30, 2025 (Second Quarter of Fiscal Year 2026) and provided a compelling update on its accelerated clinical and strategic progress. Q2 FY 2026 Strategic and Operational Highlights Strategic Financial Discipline: Executed a strategic divestiture of a non-core manufacturing facility for $2.7 million (fair value, September 29, 2025), booking a non-cash profit of approximately $1.1 million, while eliminating $600 thousand in annual operating expenses.